NO20003529L - Behandling av dyskinesi-tilstander - Google Patents

Behandling av dyskinesi-tilstander

Info

Publication number
NO20003529L
NO20003529L NO20003529A NO20003529A NO20003529L NO 20003529 L NO20003529 L NO 20003529L NO 20003529 A NO20003529 A NO 20003529A NO 20003529 A NO20003529 A NO 20003529A NO 20003529 L NO20003529 L NO 20003529L
Authority
NO
Norway
Prior art keywords
dyskinesia
treatment
conditions
levodopa
individual
Prior art date
Application number
NO20003529A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003529D0 (no
Inventor
Eldad Melamed
Ruth Djaldetti
Ilan Ziv
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12288398A external-priority patent/IL122883A0/xx
Priority claimed from IL12710298A external-priority patent/IL127102A0/xx
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Publication of NO20003529D0 publication Critical patent/NO20003529D0/no
Publication of NO20003529L publication Critical patent/NO20003529L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20003529A 1998-01-09 2000-07-07 Behandling av dyskinesi-tilstander NO20003529L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12288398A IL122883A0 (en) 1998-01-09 1998-01-09 Pharmaceutical compositions for the treatment of dyskinesias
IL12710298A IL127102A0 (en) 1998-11-17 1998-11-17 Pharmaceutical compositions for the treatment of dyskinesias
PCT/IL1999/000003 WO1999034785A2 (en) 1998-01-09 1999-01-05 Treatment of dyskinesias

Publications (2)

Publication Number Publication Date
NO20003529D0 NO20003529D0 (no) 2000-07-07
NO20003529L true NO20003529L (no) 2000-09-08

Family

ID=26323572

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003529A NO20003529L (no) 1998-01-09 2000-07-07 Behandling av dyskinesi-tilstander

Country Status (10)

Country Link
EP (1) EP1043996A2 (ko)
JP (1) JP2002500181A (ko)
KR (1) KR20010033978A (ko)
CN (1) CN1290166A (ko)
AU (1) AU1780699A (ko)
BR (1) BR9906821A (ko)
CA (1) CA2317811A1 (ko)
NO (1) NO20003529L (ko)
PL (1) PL342098A1 (ko)
WO (1) WO1999034785A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002539162A (ja) * 1999-03-12 2002-11-19 アベンテイス・フアルマ・ソシエテ・アノニム リルゾールおよびａｍｐａ受容体アンタゴニストの組み合わせ剤を用いる筋萎縮性側索硬化症の治療
FR2790670A1 (fr) * 1999-03-12 2000-09-15 Aventis Pharma Sa Association riluzole et antagoniste des recepteurs ampa
FR2801793B1 (fr) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association d'une ergoline et de riluzole et son utilisation comme medicament
US6297254B1 (en) 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease
FR2809620B1 (fr) * 2000-06-05 2002-08-02 Aventis Pharma Sa Utilisation du riluzole ou ses sels pour la prevention et le traitement de l'adrenoleucodystrophie
ES2203563T3 (es) * 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.

Also Published As

Publication number Publication date
JP2002500181A (ja) 2002-01-08
CA2317811A1 (en) 1999-07-15
PL342098A1 (en) 2001-05-21
EP1043996A2 (en) 2000-10-18
WO1999034785A2 (en) 1999-07-15
CN1290166A (zh) 2001-04-04
WO1999034785A3 (en) 1999-09-16
KR20010033978A (ko) 2001-04-25
BR9906821A (pt) 2000-10-17
NO20003529D0 (no) 2000-07-07
AU1780699A (en) 1999-07-26

Similar Documents

Publication Publication Date Title
ATE413386T1 (de) Ppar-gamma modulatoren
EP1435946B8 (en) Linked biaryl compounds
DK0858330T3 (da) Præparater indeholdende derivater af hydroperoxyeicosatetraensyre og fremgangsmåder til anvendelse ved behandling af sygdom
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
ATE344029T1 (de) Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern
DK1143955T3 (da) En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes
DE60229971D1 (de) Zubereitungen zur reizhemmenden rosacea-behandlung
MX345056B (es) Diagnóstico y tratamiento de deficiencia de sulfatasa múltiple y otras deficiencias de sulfatasa.
WO2005041924A3 (en) Administration of levodopa and carbidopa
IL145305A0 (en) 4,5-diaryl-3 (2h)-furanone derivatives as cyclooxygenase-2 inhibitors
DE69630955T2 (de) Immortalisierung bzw. desimmortalisierung von zellen
NO20061138L (no) Gjaercellevegger for behandling eller forebygging av hyperglukemi eller for a stabilisere glukemi
DK0696456T3 (da) Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme
DK1401869T3 (da) Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
NO982874L (no) Farmasöytiske preparater med vitamin D-analoger
NO20003529L (no) Behandling av dyskinesi-tilstander
NO20053053L (no) "Gap junction" peptidmodulatorer.
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
DK0994704T3 (da) Anvendelse af GABA-analoger såsom gabapentin i fremstillingen af et medikament til behandling af inflammatoriske sygdomme
AU2001258373A1 (en) Method for identifying helicobacter antigens
ATE522223T1 (de) Pflanzenextrakte
AR009819A1 (es) Inhibidores de la proteasa proteinicos estabilizados y sus variantes
DK1183037T3 (da) Sammensætninger til modulering af immunrespons og til behandling af inflammatoriske sygdomme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application